32
Participants
Start Date
September 8, 2025
Primary Completion Date
October 22, 2025
Study Completion Date
October 22, 2025
vicadrostat / empagliflozin combination 1
vicadrostat / empagliflozin combination 1
vicadrostat / empagliflozin 2
vicadrostat / empagliflozin 2
CRS Clinical Research Services Mannheim GmbH, Mannheim
Lead Sponsor
Boehringer Ingelheim
INDUSTRY